Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027

Loading news article.

Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027 | WAPE

Earlier on Monday, FDA Accepted Takeda's Application Under Priority Review for Zasocitinib (TAK-279) For Moderate-To-Severe Plaque Psoriasis, With PDUFA Action Date in Q1 2027

Article summary

Related companies

Comments —